Biotechnology - Top 100 by Market Cap

The Biotechnology Top 100 by market cap presents a selection of biotech firms, listed on the NASDAQ and NYSE

Momentum highlights the trend of the average price computed over a week, compared to the monthly price average, and is indicative of the sector's resilience

Share performances can be ranked by selected time frame, from 2 weeks to one year (default), by selection  in the top-right menu

View the Analytics for fundamental ratio details 

The biotech selection of the top 100 by market cap is not weighted- assuming one share of each component had been invested at the beginning of the selected period

ABIVAX , a French  clinical-stage biotechnology company, has been set aside because of out-of-range performance (repricing in July 2025)

The largest cap and midcap biotech themes  provide focused ranking information

• 30 Biotech LargeCap Firms (MktCap exceeding $10 billion) 
• Next 50 Biotech MidCap Firms (MktCap between $2bn and $10bn)

The iShares Biotechnology ETF  composed of an extensive list of biotechnology and pharmaceutical equities, is the benchmark of this theme

Actual performance of , the tracker fund, maybe higher or lower, depending on the weighting and  selection decided by the provider

Check the information available on the iShares Biotechnology  ETF site or contact your advisor